http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021518125-A

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15
filingDate 2019-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2021518125-A
titleOfInvention 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA composition and its usage
abstract The present invention relates to a double-stranded ribonucleic acid (dsRNA) composition that targets the HSD17B13 gene, a method of inhibiting the expression of HSD17B13, and a subject for which reduction of expression of HSD17B13 is expected to be beneficial, such as, for example. It relates to a method of treating a subject having a disease, disorder, or condition associated with HSD17B13, etc., using such a dsRNA composition. The present invention suffers from a subject for which inhibition or reduction of HSD17B13 gene expression is expected to be beneficial for inhibiting expression of the HSD17B13 gene and / or for a subject such as HSD17B13 related disease such as chronic fibroinflammatory liver disease. Also provided are methods of using the iRNA compositions of the invention for treating a subject who is or are susceptible.
priorityDate 2018-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466977536
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466243423

Total number of triples: 36.